Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 11,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 2 Interventional Results available

The Effect of Nebulized Albuterol on Donor Oxygenation

NCT00310401
Conditions
Brain Death, Organ Donor, Pulmonary Edema
Interventions
Albuterol, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
14 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oakland, California
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Remibrutinib, Ocrelizumab (US)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Glioma
Interventions
Tamoxifen citrate, Bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 65 more
Conditions
Dravet Syndrome
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
Conditions
Alzheimer's Disease
Interventions
LY450139 dihydrate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
Conditions
Epilepsy
Interventions
Perampanel Oral Tablet
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

NCT02131545
Conditions
Dementia, Delirium
Interventions
Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117
Conditions
Healthy Subjects
Interventions
PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Conditions
Brain Injury, Cognition, PTSD, Intervention
Interventions
Goal Management Training plus Attention Training, Brain Health Workshop and National Geographic Movies
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Tumors Metastatic to Brain
Interventions
sorafenib tosylate, stereotactic radiosurgery, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
ALSP
Interventions
VGL101
Drug
Lead sponsor
Vigil Neuroscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
San Francisco, California • Englewood, Colorado • Jacksonville, Florida + 2 more
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Conditions
Infection, Meningitis
Interventions
Not listed
Lead sponsor
IDbyDNA, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Orange, California • San Diego, California • Miami, Florida
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Disease Gene Identification

NCT00916903
Conditions
Congenital Vertical Talus, Familial Encephalopathy With Neuroserpin Inclusion Bodies, Idiopathic Generalised Epilepsy, Familial Dementia, X-linked Mental Retardation
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
6 Months and older
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Cerebral Palsy Infantile, Pre-Term, Motor Delay, Neurodevelopmental Disorders, Autism Spectrum Disorder
Interventions
Behavioral observation
Other
Lead sponsor
Ohio State University
Other
Eligibility
Up to 10 Days
Enrollment
46 participants
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Stroke
Interventions
Penumbra System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
Interventions
IV Zometa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Neurologic Disorders
Interventions
Laboratory tests, Radiological exams
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
4 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
44
States / cities
Dothan, Alabama • Glendale, Arizona • Little Rock, Arkansas + 38 more
Completed Not applicable Interventional Results available

rTMS for Motor and Mood Symptoms of Parkinson's Disease

NCT01080794
Conditions
Parkinson's Disease, Depression
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 2 more